Market Cap 839.98M
Revenue (ttm) 55.25M
Net Income (ttm) -334.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -605.12%
Debt to Equity Ratio -0.51
Volume 775,500
Avg Vol 1,057,928
Day's Range N/A - N/A
Shares Out 70.94M
Stochastic %K 34%
Beta 0.44
Analysts Strong Sell
Price Target $20.50

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heart...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 742 8466
Address:
100 Campus Drive, Suite 102, Florham Park, United States
jav4
jav4 Sep. 14 at 1:05 PM
$PHAT 1. Why lending + accumulating can be a smart strategy Lend shares out → institutions/hedge funds collect lending fees while shorts create selling pressure, which can push the price down. Buy more shares on dips → those same funds can quietly accumulate at cheaper prices. Recall shares later → once they want the short trade to end, they can recall the lent shares, forcing shorts to cover. That covering demand + reduced float can send the price sharply higher. So yes — if a stock is “hard to borrow” (limited float, strong insider/VC control), this strategy can be very effective.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 13 at 7:39 AM
Enter: $PHAT OCT 17 2025 $12 CALLS Buy in Price: $1.35 - $1.54 Take Profit: $1.83 Stop Bleeding: $1.36 ROI Potential: 19% Exit Within: 49 Minutes https://moneygroup.us/alerts
0 · Reply
Walleyeslayer
Walleyeslayer Sep. 12 at 5:08 PM
$PHAT remember when the shorts took it from four dollars down for two dollars before the big run. With the low volume I’m sure they will push it as hard as they can. I only bought a couple thousand at 2 bucks. Should have a great opportunity at a dip by here whenever you think they are done.
1 · Reply
Joe_90_
Joe_90_ Sep. 12 at 2:48 PM
$PHAT only 103K volume ??
1 · Reply
fgggggggg
fgggggggg Sep. 11 at 6:09 PM
$PHAT this reminds me of ticker GBT (prior to its acquisition). It was the same pattern over and over: morning dip and afternoon climb. This feels like the exact same movie and that was a great outcome.
1 · Reply
fgggggggg
fgggggggg Sep. 11 at 5:57 PM
0 · Reply
Doozio
Doozio Sep. 11 at 5:11 PM
So many $PHAT biotech STOKs during 🐒🍌🧠⏰♾️ they may even buyout MYOK like it was 🐒🍌🧠. Errrr YO $DKS ⏰♾️
0 · Reply
todd18
todd18 Sep. 11 at 5:06 PM
$PHAT buyout rumors heating up….
1 · Reply
StardustTrader
StardustTrader Sep. 11 at 2:50 PM
$PHAT 13s double top. Likely see some downside to 10-11 range. Wait to add there
3 · Reply
Jacobi
Jacobi Sep. 11 at 1:07 PM
$PHAT this is where longs need to make a decision cash on hand 150M Debt $450M They have to raise, it’s coming whether we like or not and usually companies don’t wait for the last minute to raise. Every biotech management says “we don’t need to raise” and then hit you in the face with dilution. Either a buyout or raise and the chances are more towards raise.
2 · Reply
Latest News on PHAT
Frazier Life Sciences Appoints Aditya Kohli to Partner

Apr 17, 2025, 8:00 AM EDT - 5 months ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

HLVX


Phathom Pharmaceuticals Announces Leadership Succession

Apr 1, 2025, 8:00 AM EDT - 5 months ago

Phathom Pharmaceuticals Announces Leadership Succession


Phathom Pharma Is A Buy Before July PDUFA

Jan 1, 2024, 6:41 AM EST - 1 year ago

Phathom Pharma Is A Buy Before July PDUFA


Following Up On Phathom Pharmaceuticals

Oct 5, 2023, 12:43 PM EDT - 2 years ago

Following Up On Phathom Pharmaceuticals


jav4
jav4 Sep. 14 at 1:05 PM
$PHAT 1. Why lending + accumulating can be a smart strategy Lend shares out → institutions/hedge funds collect lending fees while shorts create selling pressure, which can push the price down. Buy more shares on dips → those same funds can quietly accumulate at cheaper prices. Recall shares later → once they want the short trade to end, they can recall the lent shares, forcing shorts to cover. That covering demand + reduced float can send the price sharply higher. So yes — if a stock is “hard to borrow” (limited float, strong insider/VC control), this strategy can be very effective.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 13 at 7:39 AM
Enter: $PHAT OCT 17 2025 $12 CALLS Buy in Price: $1.35 - $1.54 Take Profit: $1.83 Stop Bleeding: $1.36 ROI Potential: 19% Exit Within: 49 Minutes https://moneygroup.us/alerts
0 · Reply
Walleyeslayer
Walleyeslayer Sep. 12 at 5:08 PM
$PHAT remember when the shorts took it from four dollars down for two dollars before the big run. With the low volume I’m sure they will push it as hard as they can. I only bought a couple thousand at 2 bucks. Should have a great opportunity at a dip by here whenever you think they are done.
1 · Reply
Joe_90_
Joe_90_ Sep. 12 at 2:48 PM
$PHAT only 103K volume ??
1 · Reply
fgggggggg
fgggggggg Sep. 11 at 6:09 PM
$PHAT this reminds me of ticker GBT (prior to its acquisition). It was the same pattern over and over: morning dip and afternoon climb. This feels like the exact same movie and that was a great outcome.
1 · Reply
fgggggggg
fgggggggg Sep. 11 at 5:57 PM
0 · Reply
Doozio
Doozio Sep. 11 at 5:11 PM
So many $PHAT biotech STOKs during 🐒🍌🧠⏰♾️ they may even buyout MYOK like it was 🐒🍌🧠. Errrr YO $DKS ⏰♾️
0 · Reply
todd18
todd18 Sep. 11 at 5:06 PM
$PHAT buyout rumors heating up….
1 · Reply
StardustTrader
StardustTrader Sep. 11 at 2:50 PM
$PHAT 13s double top. Likely see some downside to 10-11 range. Wait to add there
3 · Reply
Jacobi
Jacobi Sep. 11 at 1:07 PM
$PHAT this is where longs need to make a decision cash on hand 150M Debt $450M They have to raise, it’s coming whether we like or not and usually companies don’t wait for the last minute to raise. Every biotech management says “we don’t need to raise” and then hit you in the face with dilution. Either a buyout or raise and the chances are more towards raise.
2 · Reply
Morrito23
Morrito23 Sep. 11 at 5:25 AM
$PHAT our short interest continues to go up. About another one million shares. We are sitting at 13.72 million. Last time we we had this volume was late February when our stock price was sitting in the $5’s. Very much surprised that there are still more shorts piling up. Not sure what price they expect to drive this down to, but this new and continued rise in short interest began at about the $9 entry.
1 · Reply
Ecryder
Ecryder Sep. 10 at 7:57 PM
$PHAT added here
0 · Reply
Withermania
Withermania Sep. 10 at 7:34 PM
$PHAT no volume here. Buying at the close
0 · Reply
Walleyeslayer
Walleyeslayer Sep. 10 at 1:37 PM
$PHAT just saw 13!
1 · Reply
SocialistMoneyMan
SocialistMoneyMan Sep. 9 at 10:54 PM
$PHAT breaking news: Trump just signed a memo to crack down on direct-to-consumer pharma ads. Lower at the open??? Ugh
4 · Reply
Joe_90_
Joe_90_ Sep. 9 at 10:53 PM
0 · Reply
Jacobi
Jacobi Sep. 9 at 9:52 PM
$PHAT AI written spam
0 · Reply
Walleyeslayer
Walleyeslayer Sep. 9 at 8:11 PM
$PHAT as of August 15 there are 12.9 million shares shorted. Price continues to churn higher until….
1 · Reply
fgggggggg
fgggggggg Sep. 9 at 7:33 PM
$PHAT when do the shorts cover?
0 · Reply
RonIsWrong
RonIsWrong Sep. 9 at 7:24 PM
$PHAT could get fun here
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 9 at 6:49 AM
$PHAT Brilliant piece that captures PHAT's situation perfectly. So if you want to update your understanding of PHAT or get to know PHAT better, this is essential reading. https://beyondspx.com/quote/PHAT/analysis/phathom-pharmaceuticals-accelerating-towards-profitability-with-a-differentiated-gi-blockbuster-nasdaq-phat
0 · Reply
Nt714
Nt714 Sep. 8 at 5:31 PM
$PHAT the price went back up. I guess someone like what they hear at the conference.
1 · Reply